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Abstract
Introduction: Chagas disease, caused by the parasite Trypanosoma cruzi, can lead to long term cardiac morbidity. Treatment
of children with benznidazole is effective, but no pediatric pharmacokinetics data are available and clinical pharmacology
information on the drug is scarce.
Patients and Methods: Prospective population pharmacokinetic (PK) cohort study in children 2–12 years old with Chagas
disease treated with oral benznidazole 5–8 mg/kg/day BID for 60 days. (clinicaltrials.gov #NCT00699387).
Results: Forty children were enrolled in the study. Mean age was 7.3 years. A total of 117 samples were obtained from 38
patients for PK analysis. A one compartment model best fit the data. Weight-corrected clearance rate (CL/F) showed a good
correlation with age, with younger patients having a significantly higher CL/F than older children and adults. Simulated
median steady-state benznidazole concentrations, based on model parameters, were lower for children in our study than for
adults and lowest for children under 7 years of age. Treatment was efficacious in the 37 patients who completed the
treatment course, and well tolerated, with few, and mild, adverse drug reactions (ADRs).
Discussion: Observed benznidazole plasma concentrations in children were markedly lower than those previously reported
in adults (treated with comparable mg/kg doses), possibly due to a higher CL/F in smaller children. These lower blood
concentrations were nevertheless associated to a high therapeutic response in our cohort. Unlike adults, children have few
adverse reactions to the drug, suggesting that there may be a direct correlation between drug concentrations and
incidence of ADRs. Our results suggest that studies with lower doses in adults may be warranted.
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Introduction
Chagas disease (ChD) is a parasitic infection caused by
Trypanosoma cruzi.[1] Approximately 15 million people are
affected with ChD in Latin America, with 10,000 annual deaths
due to complications.[1,2] Infection occurs most commonly in
children, by the vectorial or congenital route. Left untreated,
ChD leads to cardiac and/or gastrointestinal morbidity and
mortality years to decades later.[1,3] ChD is endemic in the
Americas, including the US, but infected patients can also be
found in Europe, Australia, Japan and other non-endemic
countries due to migration.[4,5,3,6]
Only two medications are currently available for the treatment
of ChD, benznidazole and nifurtimox.[7,8] Even though both
drugs were developed over 4 decades ago, there is little
information available on their clinical pharmacology, particularly
for special populations such as children.[8,9]
Based on a small number of studies, treatment of pediatric ChD
with benznidazole is considered to be effective and well tolerated,
with observed response rates nearing 90% in some se-
ries.[10,8,9,11,12,13] However, treatment schedules are based
on limited data, mostly coming from the only two pharmacoki-
netics (PK) studies conducted, with a limited number of adult
patients.[14,15] No information on benznidazole PK is available
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for the pediatric population.[9,16] This lack of important data
may lead to significant risks for children, a particularly vulnerable
population.
Given this knowledge void, we have conducted the first
pediatric population PK study of benznidazole in a cohort of
children with ChD.
Methods
We enrolled children between 2 and 12 years of age with ChD
between April 2008 and November 2010 at the Parasitology and
Chagas Service, Buenos Aires Children’s Hospital ‘‘R Gutierrez’’,
Argentina.
Subjects with T. cruzi infection, defined as a positive result in at
least 2 distinct serologic tests (ELISA, Wiener Laboratory,
Rosario, Argentina; indirect hemagglutination, Polychaco Labo-
ratory, Buenos Aires, Argentina; or particle agglutination,
Fujirebio, Tokyo, Japan), and no previous treatment for ChD
were considered for inclusion. Parasitemia was evaluated by real
time polymerase chain reaction (qPCR) for parasite nuclear
satellite DNA in blood. [17,18,19] Exclusion criteria were:
pregnancy (pregnancy tests were performed for all adolescent
girls before inclusion); treatment with any investigational drug in
the month before enrollment; cardiovascular, hepatic, neurologic,
endocrine, or other major systemic diseases; and immunocom-
promised patients; Not being able to comply with the study, or to
provide consent from a guardian and assent by the child.
Patients were treated with benznidazole (Radanil, Roche, Sa˜o
Paulo, Brazil) 100 mg tablets, dose: 5-8 mg/kg/d bid p.o. for 60
days.[20,12] Tablets were fractioned by a hospital pharmacist in
an individualized manner, and re-packaged preparations with the
individual doses were provided to each patient, accompanied by
written indications for administration. Medication was provided in
monthly batches, and adherence was assessed by tablet counting at
each visit. Caregivers also completed a treatment diary to record
doses administered, times of doses, symptoms, and problems
associated to the treatment. The diary was reviewed in every clinic
visit. All patients were given a phone number to contact the
researchers if they had any questions or issues with the treatment,
and were invited back to clinic in any occasion if there were doubts
or concerns.
A detailed clinical history, physical examination, and routine
laboratory tests[20,21] were performed at diagnosis and 7, 30, and
60 days after start of treatment. Signs and symptoms suggesting
ADRs were specifically inquired for and recorded during each
hospital visit. Serologic tests for detection of antibodies against T.
cruzi were done before and at 30 and 60 days of pharmacotherapy,
and every 3–6 months after treatment. Treatment response was
evaluated by T. cruzi specific qPCR at the end of treat-
ment.[17,18,19] Cardiological evaluation, including echocardio-
gram and electrocardiogram, was conducted before the start of the
treatment and yearly afterwards, as per current clinical, and
Chagas Service, guidelines applied to all ChD patients treated in
our Hospital.
Ethics statement
The study was approved by the Ethics and Research Review
Boards, Buenos Aires Children’s Hospital ‘‘R Gutierrez’’, and the
Argentine National Drug and Food Administration (ANMAT),
Ministry of Health, Argentina. Written informed consent was
required from patients’ legal representatives, as well as assent from
the patient when appropriate. The study was registered in
clinicaltrials.gov (#NCT00699387).
Measurement of benznidazole in plasma samples
Samples for population PK analysis. At least 3 blood
samples per child were obtained at random times within pre-
specified windows. The sampling windows were as follows: for
patients taking the first dose of the drug, the three sampling
windows were: 1) 0–2 hs 2) 2–6 hs and 3) 6–12 hs post dose; for
patients at the steady state phase (i.e. at least after 3 days of
treatment; days 3–59 of treatment), the three sampling windows
were: 1) trough (i.e. before the following dose); 2) 0–2 hs and 3) 2–
6 hs post dose; finally, for patients receiving the last dose of
benznidazole, the three sampling windows: 1) 12–18 h; 2) 18–24 h
and 3) 24–36 h post dose.
Whenever possible, blood samples were taken through an IV
catheter. Thirty four patients provided 3 samples, 2 patients
provided 5 samples, 1 patient provided 4 samples and 1 patient
provided 1 sample. In the three patients with more than 3 samples,
the extra samples were opportunistically obtained from left over
blood taken for routine laboratory tests. After extraction, blood
was immediately spinned, and plasma separated, lyophilized and
stored at 24uC until analysis.
Benznidazole was measured by HPLC. Briefly, 2 mL of ethyl
acetate were added to each 1 mL of lyophilized plasma sample.
The mixture was manually shaken and precipitated with
trichloroacetic acid (30% v/v), vortexed for one minute and
sonicated for 5 minutes. The mixture was then centrifuged at
8000 g for 10 min, the supernatant put into a round bottom flask
and roto-evaporated to dryness. The residue was re-suspended in
600 mL of the chromatographic mobile phase and injected into the
HPLC system. HPLC analysis was performed by isocratic elution
with a flow rate of 1.0 ml/min with UV detection at 313 nm. The
mobile phase composition was glycine buffer/acetonitrile
(75:25 v/v). The glycine buffer was an aqueous solution of glycine
0.20 M and sodium octanesulphonate 5.0 mM at pH 2.5. The
limit of detection (LOD) and limit of quantitation (LOQ) were
0.14 mg/L, 0.32 mg/L respectively. Interday accuracy was 6.3%
and precision 3.4%. The method was linear up to 20.00 mg/
L.[22,23]
Adult data
Adult data was obtained from the original benznidazole studies
by Raaflaub et al.[14,15], which contain tables with individual
blood concentrations of benznidazole after single dose[14] and
multiple dose (30 days treatment) treatments [15], in healthy
volunteers (N= 6, all female) and adult ChD patients (N= 8, 50%
female), respectively. Mean weight of the individuals in these
Author Summary
Chagas disease is a parasitic disease endemic to the
Americas. Long term complications include severe cardiac
involvement, which can lead to severe disability and death
of affected individuals. Treatment options for Chagas
disease are limited to 2 drugs (benznidazole and
nifurtimox), but knowledge of the pharmacology of these
drugs is lacking, particularly in childhood. To date, no
pharmacokinetics data are available in children. We
conducted the first population pharmacokinetic study of
benznidazole in children. Interestingly, we found that
elimination of the drug is significantly faster in children
than in adults, leading to lower plasma concentrations.
However, unlike adults, all children in the study responded
well and had few adverse reactions to the drug. These
findings suggest that adjustment of current adult doses
may be beneficial.
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studies was 55.4 kg (sd = 7.8), and mean age was 33.3 years
(sd = 12).
Population PK (POPPK) analysis
POPPK modeling. Population PK parameters were calcu-
lated using data obtained from the children in our study, as well as
published adult data.[14,15] Adult data was added to obtain a
more comprehensive model that would encompass as wide an age
range as possible.
Structural model. POPPK modeling was carried out using
nonlinear mixed-effects modeling as implemented with NON-
MEM VII (version 7.0; ICON Development Solutions, Ellicott
City, MD). NONMEM uses mixed (fixed and random)-effects
nonlinear regression to estimate average population parameters
and inter- and intraindividual (i.e., residual) variability. A stepwise
procedure was used to find the model that offered the best fit for
the data. Classic one- and two-compartment models were
evaluated.
Covariate model. The influence of covariates was assessed
first by graphical visual inspection of PK parameters vs. the
covariates plots. Potential or known influential covariates were
incorporated sequentially into the PK model. The typical value of
a given parameter was modeled to depend linearly on each tested
covariate. Covariates tested included body weight, age, dose,
gender and whether the subject was a child or adult (i.e. data
coming from our study population or the literature). An allometric
Figure 1. Study flowchart.
doi:10.1371/journal.pntd.0002907.g001
Table 1. POPPK parameter estimates.
Parameter Median [ 95% CI] Interindividual variability [ 95% CI]
Initial model (no covariates)
Ka (h21) 0.638 h21 [0.34;1.52] 123% [48.9;300%]
V/F (L) 23.2 L [18.23;42.6] 74.2% [35.2;168.2%]
CL/F (L/h) 1.54 L/h [1.29;1.91] 61.6% [33.5;90.3%]
Residual error (Proportional) 27% [21;33.9]
Simple one-compartment model without o covariates.
doi:10.1371/journal.pntd.0002907.t001
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approach of weight on clearance (CL/F), both by using the fixed
exponential 0.75, and by allowing NONMEM to estimate the
coefficient, was also tested.
Error models. Inter-individual variations in PK parameters
were described using exponential error models. A proportional
error model was used to describe the intrapatient (residual)
variability.
Parameter estimation and model selection. Data were
fitted using a combined sequential strategy. First a Monte Carlo
importance sampling method (IMP) was used to initially estimate
parameters, followed by confirmation with the Markov chain
Monte Carlo stochastic approximation expectation maximization
(SAEM) method, as implemented in NONMEM VII with the
ADVAN5 subroutine. Model selection was based on the likelihood
ratio test, PK parameter point estimates and their respective
confidence intervals (CI), goodness-of-fit plots, and visual predic-
tive checks. Finally, a model was regarded as a statistically
significant improvement over a previous model if it produced a
decrease in objective function (DOF) of .3.84 for one additional
parameter (x2; P,0.05).
Model evaluation. The final selected model was validated on
the basis of the standard error of the estimates and visual
predictive check (VPC) plot. The bootstrap method with
replacement was used to assess stability of the final model and to
construct the CIs of the PK parameters, using PsN-Toolkit version
3.5.3. One thousand data sets were reconstructed by resampling
from the original data. Mean and 95% CI values of the parameter
estimates for each of the replicate data sets were compared with
those from the original data.
Simulation. Individual benznidazole steady-state concentra-
tions (Css) were derived from the classical Css equation:
Css = F6 (Dose6WT.ind)/(CL.ind6tau)
where F is the bioavailability of orally administered benznidazole
(set at 100% for simplicity), Dose is the daily benznidazole dose, set
at 7 mg/kg/day, WT.ind is the individual patient weight, CL.ind is
the estimated individual (Bayesian) benznidazole clearance rate (in
L/day) as per POPPK analysis, and tau is the dosing interval (set to
1 in this case, as the dose is expressed in mg/day).
All statistical calculations were performed in R statistical
language, V.2.14.1 R Foundation for Statistical Computing,
Vienna, Austria, (www.R-project.org). Diagnostic graphs were
produced in R, with the package Xpose 4.[24]
Results
Demographics
Forty children diagnosed with ChD were enrolled in the study
(Figure 1). Thirty eight patients contributed 117 samples for PK
analysis and 37 (93%) completed 60 days of treatment (one patient
contributed PK samples before withdrawing due to an adverse
drug reaction). Most patients (90%) resided in the city of Buenos
Aires or the greater Buenos Aires area, a non-endemic area for
vector transmission; the remaining patients (10%) were referred
from rural areas. Route of infection was congenital in 55% of the
patients, vectorial in 5% and undefined in 40%. Mean age was 7.3
years (SD: 3.5). Eighteen patients were girls (45%). Mean weight
was 27.2 kg (SD 12.8; range 11.5–64.0 kg). No subjects received
chronic concomitant medications. All patients were asymptomatic
with no cardiac involvement or other ChD–associated pathology,
and no comorbidities or laboratory abnormalities, at enrollment.
At diagnosis, qPCR was positive in 31/37 (84%) patients for
which samples were available. No initial samples were available for
qPCR in the remaining 3 enrolled patients due to difficult blood
extraction. Mean benznidazole dose was 6.4 mg/kg/day (SD 1;
range 5.0–8.7) in two divided daily doses. Good adherence was
observed based on tablet count and treatment diary review.
Treatment response was high, with all 37 patients who
completed 60 days of treatment having negative qPCR at the
end of treatment (day 60). All patients were followed for at least 1.5
years after treatment completion and a steady decrease of specific
T. cruzi antibodies and persistently negative qPCR was observed.
Also, qPCR was negative in all 21 patients for which samples were
available after 2 years of treatment. No cardiac involvement and
no long-term adverse consequences of treatment have been
observed in any of the patients. Most of the patients still had
positive antibodies at 2 years follow up (albeit at lower titers than
before treatment), a finding consistent with previous observations
in this age group and in adults. This confirms that antibody tests
require much longer periods of follow up for negative results to be
observed, unlike disappearance of parasitemia which commonly
occurs early after treatment.
Four (10%) patients had adverse drug reactions (ADRs) related
to benznidazole, all mild (1 mild rash, 1 moderate prurigo, 1
generalized rash without systemic involvement, and 1 moderate
eosinophilia). Mean age of children with ADRs was 8.6 years.
Three out of four children with ADRs were over 7 years old. All
ADRs subsided with symptomatic treatment (antihistamines) and
temporary drug discontinuation, and all patients recovered
uneventfully. In 2 cases rash reappeared with drug reintroduction,
requiring patient withdrawal from the study (Figure 1). These 2
patients were successfully treated with nifurtimox later on, with
good response. One further patient withdrew from the study due
to maternal decision.
Population PK analysis
Samples for population PK analysis were obtained from 38
patients (95%) in our cohort, and 14 adult patients from the
literature.[14,15] For 2 patients in our cohort, samples could not
be obtained due to early withdrawal from the study. The total
Table 2. POPPK parameter estimates.
Parameter Median [ 95% CI] Interindividual variability [ 95% CI]
Final model
Ka (h21) 0.294 h21 [0.17;0.606] 246% [99;258]
V/F (L) b0+b16WT b0=25.73 [28.106; 22.999] b1 = 0.707 [0.632;0.802] 27.05% [5;17%]
CL/F (L/h) b0+b16AGE+ (WT/70)‘b2 b0= 0.418 [0;1.654] b1 = 0.0049 [0;0.0186] b2 = 0.0743 [0;3.497] 43.35% [34;100%]
Residual error (Proportional) 27% [22.8;32.3%]
One-compartment model with covariates (weight on volume, and age and weight on clearance).
doi:10.1371/journal.pntd.0002907.t002
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number of samples for PK analysis from our cohort was 117, and
168 benznidazole plasma concentrations were obtained from
published adult data.[14,15]
Initial POPPK analysis (no covariates). A one-compart-
ment model with first-order absorption best described the
benznidazole data; no significant statistical improvement was
obtained by using a two-compartment model, zero-order absorp-
tion or other models (i.e. DOF,3.8). A proportional error model
best described residual variability.
POPPK parameters and their variability are listed in Table 1.
Briefly, Ka was 0.638 h21, V/F 23.2 L and CL/F 1.54 L/h.
Internal validity of the final model was also confirmed using
bootstrap-generated data sets. Goodness-of-fit diagnostic plots
results suggested acceptable model performance and visual
predicted check (VPC) plots for drug concentrations in plasma
showed conformity of model prediction with the observed data
(data not shown).
Individual point estimates for CL/F were significantly lower in
children in our study (,13 years old) than for adults (median 1.37
and 1.7 L/h respectively; p,0.01). Similarly, individual point
estimates for V/F were significantly different between children and
adults (median 22.98 and 32.56 L/h respectively; p,0.01).
Estimates for Ka did not differ among groups.
Covariate analysis. Stepwise covariate analysis identified
patients’ weight to have a statistically significant influence on V/F
(DOF216.34; p,0.001). Other covariates such as being a child or
an adult had statistically significant influence on V/F in univariate
analysis. However, this influence was not confirmed when added
to a multivariate model with weight, and these covariates were
therefore excluded from the final analysis. Addition of gender to
the model did not improve the fit of the data when tested on either
parameter (V/F, Ka or CL/F) in the final model. Covariate
relationships other than linear (e.g. exponential, and sigmoidal),
were evaluated but did not lead to any improvement in the fit of
the model. Also, visual inspection of the data did not support any
specific non-linear relationship for most covariates. We specifically
attempted to fit a sigmoidal relationship between CL/F and
Weight, CL/F and Age, and V/F and Weight, but the results were
disappointing.
Additional modeling, including weight as a covariate simulta-
neously on V/F and CL/F led to further improvement in the OF
(DOF 248.65; p,0.001)(Table 2). Addition of Age as a covariate
for CL/F also improved the OF (DOF 214.77; p,0.001).
Final parameter estimates were as follows:
V/F=25.73+0.7076Weight (kg)
CL/F= 0.418+0.00496Age (ys) + (Weight/70)0.0743
Figure 2. VPC plot for benznidazole concentrations in plasma vs time after each dose – final model (Covariates: Weight on V,
Weight on CL, Age on CL ). (solid line: median, discontinuous lines: 5 to 95% prediction interval).
doi:10.1371/journal.pntd.0002907.g002
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Final parameters estimates, with 95% CI, can be found in
Table 2. VPC plots for drug concentrations in plasma showed
conformity of final model prediction with the observed data
(Figure 2). Internal validity of the final model was also confirmed
using the bootstrap-generated data sets (Table 2). Goodness-of-fit
diagnostic plots results (Figure 3) suggested acceptable model
performance.
Individual weight-corrected estimates for CL/F were signifi-
cantly higher for children than for adults (median clearance
0.0615 L/Kg/h vs. 0.0301 L/Kg/h respectively; p,0.01). Chil-
dren under 7 years old had the highest weight-corrected CL/F
compared to older children and adults (Table 3). Individual
weight-corrected CL/F vs age are depicted in Figure 4.
POPPK parameter–based simulation yielded a global (children
and adults) median Css of 5.81 mg/L, with children in our study
having a median simulated Css of 4.53 mg/L (95% CI for the
median: 3.73–5.58) compared to a median Css for adults of
10.96 mg/L (95% CI for the median: 7.74–15.43). Particularly,
children under 7 years of age had lower Css (Median Css
3.61 mg/L) compared to children over 7 years old (Median Css
6.88 mg/L) and adults (Table 4).
Discussion
Acute ChD occurs mainly in children, either by congenital or
vector transmission. The acute infection is mostly asymptomatic
Figure 3. Goodness of fit plot, final model. Individual predictions vs observed data (benznidazole in mg/L).
doi:10.1371/journal.pntd.0002907.g003
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and gives way to a chronic, mostly silent, phase that can last
decades. [25,2,1] During this latter phase, internal organs may be
progressively affected, leading to cardiac involvement in approx-
imately 30% of patients. [26] In spite of the large potential public
health benefit of treating pediatric ChD cases, no new treatments
have been introduced for this population in decades, and the
pharmacology of the only two drugs available (i.e. benznidazole
and nifurtimox) was never studied in children.[8] Even though
treatment of children with ChD with benznidazole has been
shown to be safe and effective,[13,11,8,27,28,29] lack of pediatric
PK data makes dosing decisions a matter of guesswork. In fact,
currently used pediatric dosing guidelines were developed by
merely applying adult dosing to children (using weight-based
adjustments).
Benznidazole population PK modeling in our study shows that
weight-corrected CL/F is well correlated with age, with younger
patients having a significantly higher CL/F than older children
and adults. This would result in shorter half-lives (i.e. faster
elimination) and in lower accumulation in smaller children
compared to older children and adults, in the current therapeutic
context where patients are treated with weight-adjusted doses (e.g.
5–8 mg/kg/day of benznidazole).
Many reasons can explain the observed dependency of CL/F on
age. In particular, it is well-known that weight-corrected CL/F in
children 2–6 years old is significantly higher than in older children
and adults for many drugs, cleared by both the kidney or the
liver.[30,31,32] Unfortunately, to date no information is available
on the specific metabolic pathways involved in the elimination of
benznidazole, which hinders further speculation on factors that
may potentially affect its elimination, such as interactions with
other drugs or food. [33] It is possible that the observed age-
dependent variability in CL/F is a function of increasing
bioavailability (F) across ages, rather than larger clearance rate
at early ages. Unfortunately, this hypothesis is impossible to rule
out at the present time due to the lack of an intravenous
benznidazole formulation. However, this possibility seems unlikely
in light of the high lipophilicity of the drug, and animal data
suggesting complete oral absorption in mice and dogs, and due to
the fact that V/F should also be affected.[34]
Unlike children, treatment of adults with benznidazole is
associated to a significant incidence of ADRs,[11,35,32] including
severe ADRs [32,10,27,21,11,13]. Benznidazole-associated ADRs
are a frequent reason for lack of treatment adherence, and possibly
treatment failure, in adults.[11,32] The noted [10,11,13] inverse
Figure 4. Individual predicted CL/F Data for patients over 12 years old were obtained from the literature. [14,15]
doi:10.1371/journal.pntd.0002907.g004
Table 3. Weight-corrected CL/F by age group.
Age 2-7 years old 7-12 years old Adults
CL/F (L/Kg/hr) 0.0806 0.0424 0.0301
(Median [95% CI]) [0.058-0.177] [0.034-0.069] [0.027-0.033]
doi:10.1371/journal.pntd.0002907.t003
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correlation between ADRs incidence and age was also suggested
by the data in our study, with only 1 out of 4 patients with ADRs
under 7 years of age.
Mechanisms responsible for the observed age-dependent
differences in incidence of ADRs are not clear. No studies to date
have formally evaluated lower daily doses of benznidazole in
adults. In an observational study, Pinazo et al. [36] failed to find a
correlation between benznidazole trough levels and the incidence
of ADRs in a population of 54 adult patients with ChD.
Unfortunately, the PK data from this study was limited to trough
levels which may vary widely depending on time of intake of the
previous dose. Also, observed differences in drug concentrations
among adult patients were in general much smaller than those
between adults and children in our study.
We observed markedly lower benznidazole plasma concentra-
tions in children than those previously reported in adults (treated
with comparable mg/kg doses). In spite of these lower concentra-
tions, treatment in children was effective and well tolerated, with a
high response rate (as evaluated by negative qPCR at the end of
treatment) and few ADRs. Based on our results (Figure 4), we
expect that children older than 7 years old, including teenagers,
would behave more similarly to adults than to younger children
from the point of view of PK and pharmacodynamics of the drug
(e.g. incidence of ADRs). It is also conceivable that benznidazole
dose reduction for adults, to obtain systemic exposures similar to
those in children, would not have a detrimental impact on
treatment response, but may still lead to a reduction in incidence
of ADRs or at least to the development of drug sparing strategies.
Our study has some limitations that should be kept in mind
when interpreting the results. The population studied was
restricted to children 2–12 years old, making these results difficult
to extrapolate to younger patients. A population PK study of
benznidazole enrolling patients younger than 2 years of age is
currently in its final stages in our centers (clinicaltrials.gov #
NCT01549236) to address this limitation. Also, adult data
included in the analysis came from a small number of subjects
for which data was publicly available [14,15]. These subjects were
either healthy volunteers or relatively young and healthy chronic
ChD patients (i.e. without organ involvement). Therefore,
extrapolation of the results to other adults, particularly sicker
ones, should be done with care (and, ideally, within the context of
a clinical trial).
Conclusions
Observed benznidazole concentrations in children were mark-
edly lower than those reported in adults (treated with comparable
mg/kg doses). In spite of these lower concentrations, treatment
was effective and well tolerated, with few ADRs, a marked
difference from adults. If confirmed, our results would suggest that
further studies to evaluate dosing modifications in adults may be
beneficial.
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